BOSTON, May 30, 2025 /PRNewswire/ — Velsera announces that its clinical Knowledgebase is powering the interpretation framework behind Illumina’s TruSight™ Oncology Comprehensive (TSO Comp) assay, which has received regulatory approval from Japan’s Ministry of Health, Labour and Welfare (MHLW).
TSO Comp is a next-generation sequencing (NGS)-based assay that enables comprehensive genomic profiling (CGP) of solid tumors. It detects a wide range of genomic alterations including single nucleotide variants, indels, copy number changes, and gene fusions across numerous cancer-related genes from a single tumor sample.
The integration of Velsera’s Knowledgebase enables the TSO Comp test to deliver clinically actionable results by linking detected variants to curated clinical evidence, treatment guidelines, and actionability. The Knowledgebase ensures that each report reflects the most current research and regulatory data.
This approval supports Japan’s initiative to expand access to standardized, evidence-based precision oncology. TSO Comp, now commercially available in Japan, is positioned to help clinicians make more informed treatment decisions and improve outcomes for patients with cancer.
Velsera’s contribution reinforces its mission to connect healthcare and clinical decision support through actionable data, accelerating the delivery of genomics insights in clinical care. Velsera’s clinical portfolio will be featured at ASCO May 31st – June 2nd, 2025.
Learn more about our solutions here: https://velsera.com/products/knowledgebase/
About Velsera
Velsera’s mission is to be the discovery, evidence generation, and clinical delivery platform for precision medicine. We help experts in clinical diagnostics and life sciences make better decisions about providing the right therapy to the right patients at the right time. Velsera was founded in 2023 as a result of the merger of Seven Bridges, PierianDx and UgenTec and operates in the US, Europe and Asia. To learn more, visit velsera.com.
Contacts
Velsera
Brian Lassiter
919-538-5611
395956@email4pr.com
SOURCE Velsera
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…